Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 6.2% in November

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 20,330,000 shares, an increase of 6.2% from the November 15th total of 19,140,000 shares. Currently, 19.6% of the shares of the stock are sold short. Based on an average trading volume of 3,040,000 shares, the short-interest ratio is currently 6.7 days.

Humacyte Stock Performance

NASDAQ HUMA traded down $0.54 on Tuesday, reaching $3.80. The stock had a trading volume of 5,753,557 shares, compared to its average volume of 2,429,610. Humacyte has a 1-year low of $2.48 and a 1-year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The company has a market cap of $477.63 million, a P/E ratio of -3.04 and a beta of 1.38. The firm has a fifty day moving average of $4.96 and a two-hundred day moving average of $5.93.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on HUMA shares. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of Humacyte in a research report on Wednesday, November 13th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday, November 21st. Benchmark reiterated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Humacyte presently has an average rating of "Buy" and a consensus price target of $13.00.

Insiders Place Their Bets

In related news, Director Brady W. Dougan sold 427,459 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company's stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Insiders own 11.20% of the company's stock.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of Humacyte during the 2nd quarter worth approximately $28,000. Concurrent Investment Advisors LLC acquired a new position in Humacyte in the 3rd quarter valued at $75,000. Principal Financial Group Inc. bought a new stake in shares of Humacyte during the 2nd quarter valued at $83,000. FORA Capital LLC bought a new stake in shares of Humacyte during the 3rd quarter valued at $96,000. Finally, Insigneo Advisory Services LLC acquired a new stake in shares of Humacyte during the 3rd quarter worth $109,000. Institutional investors and hedge funds own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.